CFON-026
B-cell malignancies (via BTK inhibition)
Key Facts
About Crossfire Oncology
Crossfire Oncology is a private, preclinical-stage biotech developing a next-generation portfolio of kinase-targeting therapies through its proprietary EPriL (Energetically Privileged Ligands) platform. The company's strategy involves selecting from three distinct modalities—inhibitors, degraders, and Degrader Antibody Conjugates (DACs)—to optimally match the biological profile of each kinase target, aiming for improved efficacy and reduced toxicity. Its most advanced internal program, CFON-026, is a non-covalent BTK inhibitor planned to enter clinical trials in the second half of 2025. The team comprises seasoned veterans in medicinal chemistry with a track record of designing drugs that have advanced into clinical development.
View full company profile